Last reviewed · How we verify
Drug: ipratropium (AtroventTM)
Ipratropium is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the airways to reduce bronchoconstriction and mucus secretion.
Ipratropium is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the airways to reduce bronchoconstriction and mucus secretion. Used for Chronic obstructive pulmonary disease (COPD), Asthma, Rhinorrhea associated with allergic and non-allergic rhinitis.
At a glance
| Generic name | Drug: ipratropium (AtroventTM) |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Anticholinergic bronchodilator |
| Target | M3 muscarinic acetylcholine receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Ipratropium competitively antagonizes acetylcholine at M3 muscarinic receptors on airway smooth muscle and mucus glands. This prevents acetylcholine-induced bronchoconstriction and reduces mucus production, leading to bronchodilation and improved airflow. As a quaternary ammonium compound, it is poorly absorbed systemically and acts locally in the lungs when inhaled.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
- Asthma
- Rhinorrhea associated with allergic and non-allergic rhinitis
Common side effects
- Dry mouth
- Tremor
- Headache
- Nervousness
- Palpitations
Key clinical trials
- Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Drug: ipratropium (AtroventTM) CI brief — competitive landscape report
- Drug: ipratropium (AtroventTM) updates RSS · CI watch RSS
- AstraZeneca portfolio CI